Lee Davies, a spokesman for the Merck and Schering-Plough joint venture that sells Vytorin, said the companies were in the process of responding to all the lawmakers' requests for information in the Vytorin probe and would answer the newest letter.
The lawmakers also sent letters requesting information about who may have posted the messages to Cafepharma.com and SoftLayer Technologies Inc, which they said operates the Web site. Officials at those companies could not immediately be reached for comment.
In addition, Dingell and Stupak asked the FDA for records about the Enhance study protocol, health problems reported with Vytorin, and other information. FDA spokeswoman Susan Cruzan said the FDA would review the letter and respond.
